Tangent Medical has filed NovaCath Secure IV catheter system's 510(k) application with the US Food and Drug Administration (FDA).
The new closed IV catheter system is a next-generation technology which is designed to address many complex IV therapy challenges including catheter stabilization, occupational exposure to blood and patient discomfort.
Tangent Medical sales and marketing vice president Curtis Bloch said the NovaCath Secure IV System is a new IV catheter designed to advance the safety and welfare of both patients and healthcare workers.
Tangent Medical CEO and chairman Jeff Williams said the initial feedback on the NovaCath Secure IV catheter system design has been positive from both industry professionals and potential users.
"We are excited to announce NovaCath’s submission milestone and look forward to working with the FDA through the review process to gain 510(k) marketing clearance," Williams added.